Skip to main content

What the FDA labels say about taking them together

Fosamprenavir and quinidine

Fosamprenavir's FDA label of September 15, 2023 names quinidine in its drug interactions section; the quinidine label PlainMeds reads does not name fosamprenavir. The fosamprenavir label: “Therapeutic concentration monitoring, if available, is recommended for antiarrhythmics.”

Check it at the source: the fosamprenavir FDA label on DailyMed (effective September 15, 2023, Mylan Pharmaceuticals Inc.); the quinidine FDA label on DailyMed (effective February 1, 2018, Sun Pharmaceutical Industries, Inc.).

What does the fosamprenavir label say about quinidine?

Fosamprenavir label, drug interactions

Concomitant Drug Class/Drug Name: Antiarrhythmics: Amiodarone, disopyramide, lidocaine (systemic), and quinidine; Effect on Concentration of Amprenavir or Concomitant Drug: ↑ Antiarrhythmics; Clinical Comment: Therapeutic concentration monitoring, if available, is recommended for antiarrhythmics.

Source: FDA drug label (Fosamprenavir Calcium), Mylan Pharmaceuticals Inc., effective September 15, 2023 (SPL set 3a1424d8-844c-4e24-9ebd-b2c2b61b61a3), via openFDA; the full label on DailyMed

What does the quinidine label say about fosamprenavir?

Quinidine's label (effective February 1, 2018) does not name fosamprenavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Quinidine Gluconate), Sun Pharmaceutical Industries, Inc., effective February 1, 2018 (SPL set 5023f053-fcc4-4c2c-aa59-9ec198ad185e), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

2Fosamprenavir generic labelers
4Quinidine generic labelers
FosamprenavirQuinidine
Labeled forHIVAtrial fibrillation
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$4.92 per tablet 324 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?